2019年12月我国湖北武汉爆发的新型冠状病毒（SARS-CoV-2）引起的肺炎（COVID-19）与2002年严重急性呼吸综合征（SARS）、2012年中东呼吸综合征（MERS）均属于冠状病毒引起的传染性疾病。根据对SARS和MERS等传染病的认识，许多患者和医护人员在疫情期间、疫情之后均会产生抑郁、焦虑等紧张情绪，尤其疫后幸存者患创伤后应激障碍（PTSD）的几率会大大增高；COVID-19疫情期间和疫后也会出现类似情况。因此，缓解灾难时感染患者、一线医护人员、隔离人员等人群的紧张情绪，尽可能地降低COVID-19疫后PTSD发病率，也是防控此次疫情的一项重要任务。中医药治疗情感类疾病有独特优势，从中医理论角度认识PTSD的病因病机，寻找治疗PTSD的有效方法，将会对治疗疫后幸存者的PTSD有所帮助。通过对治疗PTSD相关中药的研究进行汇总和对比，发现疏肝解郁方四逆散在治疗PTSD方面有潜在价值。因此，四逆散可作为COVID-19疫情期间缓解患者及相关人员的抑郁和焦虑症状，以及疫情之后治疗PTSD的首选基础方药，以期从心理精神方面帮助战胜COVID-19。

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, Hubei Province in December 2019, with severe acute respiratory syndrome (SARS) in 2002 and Middle East respiratory syndrome (MERS) in 2012 are all infectious diseases caused by coronavirus. According to the knowledge of infectious diseases such as SARS and MERS, many patients and health care workers suffered from depression and anxiety during and after the epidemic. In particular, post-epidemic survivors were more likely to suffer from post-traumatic stress disorder (PTSD). Similar conditions could be occurred during and after COVID-19. Therefore, it is also an important task to reduce the prevalence of PTSD after COVID-19 as much as possible and to relieve the tension of infected patients, first-line medical staff, quarantine personnel and so on. Traditional Chinese medicine has unique advantages in the treatment of emotional diseases. Understanding the etiology and pathogenesis of PTSD by theory of traditional Chinese medicine and looking for effective methods to treat PTSD will be helpful to treat PTSD of survivors after COVID-19. It is found that Sini Powder has potential value in the treatment of PTSD by the summary and comparison of the research on traditional Chinese medicine related to the treatment of PTSD. We hope to overcome this epidemic psychologically and spiritually. Therefore, it is considered that Sini Powder can be used as the first choice for relieving emotional diseases of related patients during COVID-19 and treating PTSD of survivors after COVID-19.

R285

国家自然科学基金资助项目（81460611）；2020年度甘肃省重大疾病分子医学与中医药防治研究重点实验室新型冠状病毒防治研究专项开放基金（FZYX20-10）